Elicio Therapeutics, a next generation immuno-oncology company, has completed its USD33m Series B financing, it was reported yesterday.

The funds will be utilised to advance the company's range of novel lymph node targeted immuno-therapies, including ELI-002, an Amphiphile mKRAS vaccine.

Robert Connelly, CEO of Elicio, said, We believe ELI-002 can become a universal mKRAS vaccine with the potential to treat and prevent disease recurrence for hundreds of thousands of patients with mKRAS-driven cancers, including pancreatic, colorectal and lung cancer. This new funding is a strong endorsement of this program, the Amphiphile platform, and our progress.'